Non-executive Chairman: Peter Allen
Peter joined Proximagen as Chairman in February 2009 and brings a wealth of experience to the role. Peter has held a number of senior roles in the biotechnology industry having been Chief Financial Officer of Celltech Group plc between 1992 and 2004. Peter was also Chief Financial Officer of Abacus Group plc from 2005 until 2009. He is currently the Chairman and acting Chief Executive of ProStrakan Group plc and the nonexecutive Chairman of Chroma Therapeutics Limited. Peter is a chartered accountant and his early career included financial controller roles at Associated British Ports and L’Oreal (UK).
Chief Executive Officer: Kenneth Mulvany
Kenneth joined Proximagen in April 2004 as Chief Executive Officer and since then, under his leadership, Proximagen has grown from a small privately held company to one of the best-funded biotechnology companies in Europe with an exciting pipeline of drug candidates. Kenneth began his career at Scripps Research Institute and gained pharmaceutical industry experience at Merck. Prior to Proximagen, Kenneth played a key role in developing several successful high-tech start-ups. He brings 16 years of technology and business expertise to the Group.
Finance Director: James Hunter
James joined the Group in January 2005 as Financial Controller and was subsequently appointed to the Board in February 2006. James joined Proximagen after spending six years in the corporate finance team at Ernst & Young where he worked in mergers and acquisitions and corporate restructuring. James has an MBA from the Cranfield School of Management.
Non-executive Director: Michael Ashton
Michael joined the Board in December 2005. He has more than 30 years’ experience in the pharmaceutical industry having worked for Merck Inc., Pfizer Inc., Purepac Inc., Faulding Inc. and SkyePharma plc as CEO. Michael is also a non-executive director of Hikma Pharmaceuticals plc, Transition Therapeutics Inc and Puricore plc .
Non-executive Director: Dr Jackie Hunter CBE
Jackie joined the Board in January 2010. She was previously the Senior Vice President and Head of Science Environment Development at GSK, and prior to that she was the Senior Vice President and Head of the Neurology & GI Centre of Excellence for Drug Discovery (“CEDD”) at GSK, during which time the CEDD delivered over 15 clinical proofs of concept studies with a number of transitions into late-phase development. Jackie is a director of OI Pharma Partners Ltd and is an internationally recognised expert in neuroscience R&D. She is a Trustee of the charity, Age Care and a member of the Science Advisory Board of the Motor Neurone Disease Association. Most recently she was appointed a lay member of the Governing Council of Royal Holloway College, University of London.